131. What's on the Horizon in TB Treatment?
Session: Symposium: Update on TB Diagnostics and Treatment of Complex, Multidrug-Resistant TB
Friday, October 21, 2011: 9:51 AM
Room: 253ABC

Eric Nuermberger, MD, Medicine, Johns Hopkins University, Baltimore, MD

Dr. Nuermberger received his MD degree from Vanderbilt University Medical School in 1996. He completed his residency in Internal Medicine (1999) and fellowship in Infectious Diseases (2003) at Johns Hopkins Hospital. From 2000-2001, he served as Assistant Chief of Service in the Department of Medicine. He joined the faculty of the Division of Infectious Diseases in 2003 and was promoted to Associate Professor in 2009. In addition to his activities in clinical care, teaching and research, he serves on the Antibiotic Subcommittee of the Pharmacy and Therapeutics Committee for the hospital.
Dr. Nuermberger’s research interests are pre-clinical development of new drugs for tuberculosis and the pharmacokinetics and pharmacodynamics of antimicrobial therapy. He is a member of the Editorial Board for Antimicrobial Agents and Chemotherapy and an Associate Editor of the International Journal of Tuberculosis and Lung Disease. He has received research support from the National Institutes of Health, the Bill and Melinda Gates Foundation, the Global Alliance for TB Drug Development, the Food and Drug Administration, and several pharmaceutical companies.

<< Previous Presentation | Next Presentation

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.